DNA X, Inc. SONM
Nasdaq · XNAS · stock · Telephone & Telegraph Apparatus
Chart by TradingView
1/9
Piotroski F — financial health
-26.83
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$20.7M | — | — | -$8.0M |
| 2024 | $58.3M | -$33.6M | $9.9M | -$8.7M | -$5.7M |
| 2023 | $93.6M | -$90,000 | $19.3M | -$4.1M | $22.4M |
| 2022 | $69.8M | -$14.1M | $11.6M | -$12.4M | $20.0M |
| 2021 | $54.6M | -$38.6M | $6.4M | -$38.5M | $18.6M |
| 2020 | $64.0M | -$29.9M | $15.2M | -$10.6M | $28.4M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -26.83 (distress)
- Working capital / assets -0.495
- Retained earnings / assets -6.931
- EBIT / assets -0.123
- Equity / liabilities -0.157
Source: SEC EDGAR filings · CIK 0001178697 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.